Skip to content
AnalystLens

Merck Annual Report, Year Ended Dec 31, 2012

Filing Date
Filed February 28, 2013
Period End
December 31, 2012
Security
MRK
In the record · 2016–202610-K1210-Q338-K87

MRK filed 12 annual reports (10-K), 33 quarterly reports (10-Q) and 87 current reports (8-K) between 2016 and 2026.

  1. Impairment8-K · Feb ’17Feb ’17
  2. Restructuring8-K · Apr ’19Apr ’19
  3. Leadership change8-K · Aug ’21Aug ’21
  4. Restructuring8-K · Jul ’25Jul ’25

Summary

Summary of the 10-K filed February 28, 2013. Cited figures are marked; the original filing is the authoritative source.

Merck & Co., Inc. reported $47.3 billiona in worldwide sales for 2012, a slight 2% decrease from 2011, impacted by the U.S. patent expiration of Singulair.

Despite this, the company demonstrated resilience with a 1%b sales increase excluding foreign exchange impacts, driven by growth in key products like Januvia, Janumet, Gardasil, and Victrelis. Merck continued to focus on cost management, reducing operating expenses, and advancing its robust research and development pipeline, with several key drug candidates under regulatory review and in late-stage development. The company also highlighted strategic growth initiatives, including geographic expansion into high-growth markets, expansion into complementary Animal Health and Consumer Care businesses, and continued investment in innovation.

Despite facing pricing pressures globally and the ongoing impact of healthcare reform, Merck demonstrated strong operational execution and maintained its commitment to returning capital to shareholders through dividends and share repurchases. The company also addressed significant legal settlements, notably the ENHANCE litigation, which impacted 2012 earnings but was covered by insurance recoveries.

Key Highlights

  1. Worldwide sales of $47.3 billion for 2012, a 2% decrease from 2011, primarily due to the Singulair U.S. patent expiration.
  2. Sales excluding foreign exchange increased by 1%, indicating underlying operational strength driven by key products like Januvia and Gardasil.
  3. Significant R&D pipeline advancement with multiple drug candidates under regulatory review and in Phase III development.
  4. Strategic focus on cost management led to reduced operating expenses and achievement of merger-related cost savings.
  5. Continued investment in high-growth emerging markets, with China showing a notable 25% sales increase.
  6. Animal Health and Consumer Care segments showed solid growth, contributing positively to overall performance.
  7. The company incurred a $493 million charge for the ENHANCE litigation settlement in 2012, partially offset by insurance recoveries.

Financial Statements

FY2012 against FY2011

Line itemFY2012FY2011Change
Revenue$47.27B$48.05B−1.6%
Cost of Revenue$16.45B$16.87B−2.5%
Gross Profit$30.82B$31.18B−1.1%
R&D Expenses$8.17B$8.47B−3.5%
SG&A Expenses$12.78B$13.73B−7.0%
Interest Expense$714.00M$695.00M+2.7%
Net Income$6.17B$6.27B−1.7%
EPS (Basic)$2.03$2.04−0.5%
EPS (Diluted)$2.00$2.02−1.0%
Shares Outstanding (Basic)3.04B3.07B−1.0%
Shares Outstanding (Diluted)3.08B3.09B−0.6%

Frequently Asked Questions

  1. What was the primary driver of the sales decline in 2012?

    The primary driver of the sales decline in 2012 was the U.S. patent expiration for Singulair in August 2012, which resulted in a significant and rapid decrease in its sales, particularly in the fourth quarter.

  2. How is Merck managing its R&D pipeline and what are the key areas of focus?

    Merck is advancing its R&D pipeline with four candidates under regulatory review and 16 in Phase III development. Key focus areas include diabetes, cardiovascular diseases, cancer, infectious diseases, and vaccines. The company is also leveraging external alliances and licensing agreements to supplement internal research efforts.

  3. What are the major risks and challenges Merck faces as highlighted in the filing?

    Merck faces significant risks including: loss of market exclusivity for key products due to patent expirations leading to generic competition; intense competition from other pharmaceutical companies; pricing pressures from healthcare cost containment efforts globally; regulatory scrutiny and changes in healthcare laws; and potential failures in R&D, which can result in substantial investments without commercial return. Litigation, such as the Vioxx and Fosamax cases, also presents ongoing financial and operational risks.

  4. How did the merger with Schering-Plough impact the company's cost structure and financial performance?

    The merger with Schering-Plough led to a significant restructuring program aimed at optimizing the cost structure of the combined company. This involved workforce reductions and site rationalizations, resulting in substantial restructuring costs but also projected annual savings. As of the end of 2012, the company had achieved its projected $3.5 billion in annual net cost savings from these activities.